Physician profile

Mark A Checcone

Otolaryngology/Facial Plastic Surgery · Sarasota, FL

NPI 1548463839

$379.77

in general payments reported to CMS, 2019-2025

6 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$174.98

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Merz North America, INC. $217.03 2021-2024 Xeomin
Sientra, INC. $76.19 2020-2021
Stryker Corporation $30.92 2019
Abbvie INC. $19.38 2024
Cochlear Americas $18.26 2024 Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode, Baha, Osia Osi300 Implant
Vertical Pharmaceuticals, LLC $17.99 2024 Dsuvia

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Mark A Checcone

$379.77

in general payments reported 2019-2025

Years
2019-2024
Top company
Merz North America, INC.

https://glasscript.com/doctor/206709/mark-a-checcone

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.